SCHEMBL3283442

SCHEMBL3283442

Cn1ncc2cc(Nc3nc(Nc4ccc(C(N)=O)cc4)nc4[nH]ccc34)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.55
PTK2 Q05397 10/20 0.47
SYK P43405 3/20 0.47
IGF1R P08069 2/20 0.43
AURKB Q96GD4 2/20 0.43
BRD4 O60885 2/20 0.43
CREBBP Q92793 1/20 0.43
JAK2 O60674 2/20 0.42
SGK1 O00141 1/20 0.42
CHEK1 O14757 1/20 0.42
AURKA O14965 1/20 0.42
DAPK3 O43293 1/20 0.42
PRKAB2 O43741 1/20 0.42
ROCK2 O75116 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
PAK4 O96013 1/20 0.42
ABL1 P00519 1/20 0.42
NTRK1 P04629 1/20 0.42
INSR P06213 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283548 0.93 LRRK2 (0.57) LRRK2PTK2SYKIGF1RAURKB
SCHEMBL14287378 0.78 LRRK2 (0.69) LRRK2PTK2SYKIGF1RAURKB
SCHEMBL3286833 0.78 LRRK2 (0.57) LRRK2PTK2SYKDAPK3ROCK2
SCHEMBL3286256 0.78 PTK2 (0.43) PTK2SYKBRD4CREBBPJAK2
SCHEMBL13387179 0.77 LRRK2 (0.54) LRRK2PTK2SYKIGF1RAURKB
SCHEMBL3286230 0.76 SYK (0.41) PTK2SYKBRD4CREBBPTGFBR1
SCHEMBL5119258 0.75 LRRK2 (0.65) LRRK2PTK2SYKIGF1RAURKB
SCHEMBL14287388 0.75 LRRK2 (0.68) LRRK2PTK2SYKIGF1RAURKB
SCHEMBL13951468 0.75 LRRK2 (0.54) LRRK2PTK2SYKIGF1RAURKB
SCHEMBL3279212 0.74 BRD4 (0.53) PTK2SYKBRD4CREBBPJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US claimed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 WO claimed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US claimed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK LRRK2 276/4885PTK2 196/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.